Tiwari Group's forward integration into WHO-GMP pharmaceutical manufacturing — beta-lactam, cephalosporins and general formulations.
Established as the flagship manufacturing company of Tiwari Group, Sucantis Biotech delivers third-party and export formulations from dedicated beta-lactam, cephalosporin and general manufacturing blocks.
With ₹125 crore invested across Unit-1 (Haridwar) and Unit-2 (Kathua, J&K), we combine modern infrastructure, experienced leadership and rigorous quality systems for long-term CDMO partnerships. CIN: U24299HR2021PTC099275.
To become a globally trusted pharmaceutical partner by delivering innovative, accessible, and compliant medicines that improve health outcomes.
To manufacture and supply a wide range of formulations that meet the highest quality standards, leveraging modern facilities and ethical business practices.
From branded domestic marketing to bulk third-party supply and merchant export — one WHO-GMP platform serving multiple go-to-market models.
Under the Herbert David brand, Sucantis markets dry syrups, dry injections, capsules and tablets across India — building trust with prescribers, distributors and pharmacies.
ISO-, GMP- and GLP-compliant bulk supply for pharma marketers and sellers who need high-quality, affordable formulations at volume.
Export through merchant exporters to African markets with reliable manufacturing, batch compliance and timely dispatch.
| Dosage Form | Beta-Lactam | Cephalosporin | General |
|---|---|---|---|
| Tablets | 1500 million / annum | 1500 million / annum | 600 million / annum |
| Capsules | 300 million / annum | 200 million / annum | — |
| Dry Syrups | 20 million / annum | 20 million / annum | 5 million / annum |
With over 30 years in pharmaceuticals, Mr. Dilip Kumar Tiwari brings unmatched leadership and operational expertise. An MBA by qualification, he has led several successful ventures and is the strategic force behind our quality-focused, growth-driven approach.
Three decades of pharmaceutical industry experience supporting Tiwari Group's expansion and Sucantis Biotech's long-term manufacturing vision.
15+ years in the pharmaceutical sector. His understanding of market dynamics, team management and distribution channels ensures Sucantis Biotech's strong presence across India and export markets.
Contributes strategic oversight and operational support across Tiwari Group's forward integration into pharmaceutical manufacturing.
Holds a Bachelor's degree in Pharmacy with hands-on involvement in operations and product development — helping the company stay innovative and efficient in its offerings.
Over 20 years in product development and plant operations with Biogenetic Drugs and Associated Biotech. He supervises technical professionals through the full cycle of developing and commercialising differentiated, quality products.
Two decades of electrical and plant infrastructure expertise supporting reliable utilities, equipment and facility operations across manufacturing units.
Electrical engineering background supporting plant infrastructure, maintenance systems and operational reliability at Sucantis facilities.
Fellow Chartered Accountant providing strategic financial guidance — corporate finance, investment planning, capital structuring, debt syndication, treasury management and risk mitigation for sustainable growth.
16+ years in QA at Acme Formulations, Zydus Healthcare, Akums Drugs and East African India Overseas. Led WHO-Geneva, Uganda FDA, Philippines, Tanzania, Kenya, Ghana and ROW regulatory inspections.
13+ years in QC at Dhanuka Laboratories, Mascot Health Series and Ravian Lifesciences. Expertise in QC lab setup, GLP strengthening and WHO-GMP regulatory inspections.
20+ years at Emcure Pharma, Lupin, Glenmark and Ranbaxy. Extensive GLP and QMS expertise with USFDA, MHRA, EU and WHO-Geneva regulatory experience.
Our facilities are designed for consistent output with top-tier quality and compliance — separate production zones for dry syrups, tablets, capsules and dry injections.
ISO 9001:2015, GMP, GLP and WHO-GMP certifications; manufacturing licenses for Unit-1 (Nov 2023) and Unit-2 (May 2025).
Successfully launched over 500 formulations across beta-lactam, cephalosporin and general ranges.
Branded Herbert David operations across India; merchant export to 4+ African countries with recurring buyer relationships.
Internal R&D, documentation and vendor audit systems — zero regulatory non-compliance issues to date.
India's pharmaceutical industry is the 3rd largest globally by volume and 13th by value, contributing over 20% of worldwide generic drug exports. The domestic market was valued at ₹2.9 lakh crore in FY 2023 and is projected to grow at 10–12% CAGR — driven by rising healthcare awareness, a growing middle class, Jan Aushadhi schemes, expanding insurance penetration and increasing NCD burden.
Sucantis Biotech is positioned at the intersection of this growth — combining Tiwari Group's distribution strength, WHO-GMP manufacturing infrastructure and flexible business models for domestic brands, third-party partners and African export channels.
Product brief, regulatory scope and capacity alignment across beta, cepha or general blocks.
Formulation, stability and process validation under QA oversight.
Batch manufacturing with in-process controls and COA release.
Dispatch with batch records, certificates and export documentation as required.
Every batch released through documented GMP controls — from vendor qualification to finished-goods testing.
Transparent timelines, regulatory documentation and dedicated blocks for beta-lactam and cephalosporin supply.
Formulations for Indian pharma companies and export markets with neutral code and dossier support.
Key slides from the official Sucantis Biotech profile — market positioning, business model, certifications and manufacturing excellence. Download full PDF.
We welcome serious manufacturing partners for plant visits and technical discussions.
Get in Touch